Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetic immunization is augmented by murine polyomavirus VP1 pseudocapsids.

E Rollman1, T Ramqvist, B Zuber

  • 1Department of Virology, Swedish Institute for Infectious Disease Control and the Microbiology and Tumor Biology Center, Karolinska Institute, SE-171 82, Solna, Sweden. erik.rollman@smi.ki.se

Vaccine
|May 15, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrasensitive Label-Free Detection of Protein-Membrane Interaction Exemplified by Toxin-Liposome Insertion.

The journal of physical chemistry letters·2022
Same author

Lung transplantation for COVID-19-associated acute respiratory distress syndrome: The first French patient.

Respiratory medicine and research·2021
Same author

Primordial GATA6 macrophages function as extravascular platelets in sterile injury.

Science (New York, N.Y.)·2021
Same author

Impact of intensive care unit relocation and role of tap water on an outbreak of Pseudomonas aeruginosa expressing OprD-mediated resistance to imipenem.

The Journal of hospital infection·2018
Same author

Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.

Scientific reports·2018
Same author

HIVIS-DNA or HIVISopt-DNA priming followed by CMDR vaccinia-based boosts induce both humoral and cellular murine immune responses to HIV.

Heliyon·2017

Murine polyomavirus pseudocapsids enhanced DNA immunization, significantly boosting antibody titers against HIV-1 proteins. This carrier/adjuvant effect shows promise for improving humoral immune responses in DNA vaccination strategies.

Area of Science:

  • Immunology
  • Virology
  • Vaccine Development

Background:

  • DNA immunization is a promising strategy for inducing immune responses.
  • Enhancing the efficacy of DNA vaccines remains a critical challenge.
  • The use of viral pseudocapsids as carriers is being explored to improve vaccine delivery and immunogenicity.

Purpose of the Study:

  • To investigate the potential of murine polyomavirus major capsid protein (VP1) pseudocapsids as a carrier and adjuvant for DNA immunization.
  • To evaluate the impact of VP1 pseudocapsid complexation on immune responses against human immunodeficiency virus type 1 (HIV-1) p37 nucleocapsid proteins.

Main Methods:

  • Complexing a DNA plasmid encoding HIV-1 p37 proteins with murine polyomavirus VP1 pseudocapsids.
  • Administering the DNA-VP1 complex or DNA plasmid alone to mice.

Related Experiment Videos

  • Measuring antibody titers and cell-mediated immune responses.

    • Main Results:

    • A 10-fold increase in antibody titer was observed in mice receiving the DNA-VP1 complex compared to those receiving DNA alone.
    • Cell-mediated responses to HIV-1 p24 were detected but not significantly augmented by the VP1 complex.
    • Polyomavirus pseudocapsids demonstrated a strong carrier/adjuvant effect, significantly increasing humoral immune responses.

    Conclusions:

    • Murine polyomavirus VP1 pseudocapsids can act as effective carriers and adjuvants in DNA immunization.
    • This approach significantly enhances humoral immune responses, specifically antibody production.
    • Further research into VP1 pseudocapsid-based DNA vaccines may lead to improved strategies for infectious disease prevention.